Rekombinanter TNFRSF18 (Ragifilimab Biosimilar) Antikörper
Kurzübersicht für Rekombinanter TNFRSF18 (Ragifilimab Biosimilar) Antikörper (ABIN7581718)
Target
Antikörpertyp
Reaktivität
Wirt
Klonalität
Konjugat
Applikation
-
-
Expressionssystem
- CHO Cells
-
Verwendungszweck
- Anti-TNFRSF18 / GITR / CD357 Reference Antibody (ragifilimab)
-
Sequenz
- QVQLVQSGAE VKKPGASVKV SCKGSGYTFT DYAMYWVRQA PGQGLEWIGV IRTYSGDVTY NQKFKDRATM TVDKSISTAY MELSRLRSDD TAVYYCAKSG TVRGFAYWGQ GTLVTVSSAS TKGPSVFPLA PSSKSTSGGT AALGCLVKDY FPEPVTVSWN SGALTSGVHT FPAVLQSSGL YSLSSVVTVP SSSLGTQTYI CNVNHKPSNT KVDKRVEPKS CDKTHTCPPC PAPELLGGPS VFLFPPKPKD TLMISRTPEV TCVVVDVSHE DPEVKFNWYV DGVEVHNAKT KPREEQYNST YRVVSVLTVL HQDWLNGKEY KCKVSNKALP APIEKTISKA KGQPREPQVY TLPPSREEMT KNQVSLTCLV KGFYPSDIAV EWESNGQPEN NYKTTPPVLD SDGSFFLYSK LTVDKSRWQQ GNVFSCSVMH EALHNHYTQK SLSLSPGK,DIVMTQSPDS LAVSLGERAT INCKSSQSLL NSGNQKNYLT WYQQKPGQPP KLLIYWASTR ESGVPDRFSG SGSGTDFTLT ISSLQAEDVA VYHCQNDYSY PYTFGQGTKL EIKRTVAAPS VFIFPPSDEQ LKSGTASVVC LLNNFYPREA KVQWKVDNAL QSGNSQESVT EQDSKDSTYS LSSTLTLSKA DYEKHKVYAC EVTHQGLSSP VTKSFNRGEC
-
Produktmerkmale
- Anti-TNFRSF18 / GITR / CD357 Reference Antibody (ragifilimab) is expressed from CHO. The heavy chain type is huIgG1, and the light chain type is hukappa. It has a predicted MW of 145.5 kDa.
-
Reinheit
- >95 %
-
Isotyp
- IgG1
-
-
-
-
Applikationshinweise
- Optimal working dilution should be determined by the investigator.
-
Kommentare
-
Therapeutic Agents by Target and Mechanism: GITR agonist
-
Beschränkungen
- Nur für Forschungszwecke einsetzbar
-
-
-
Format
- Lyophilized
-
Konzentration
- 1 mg/mL
-
Buffer
- 25 mM histidine, 8 % sucrose, 0.01 % Tween80 pH 6.2
-
Lagerung
- 4 °C,-80 °C
-
Informationen zur Lagerung
- +4°C,-80°C
-
-
- TNFRSF18 (Ragifilimab Biosimilar)
-
Substanzklasse
- Biosimilar
-
Molekulargewicht
- 145.5 kDa
-
UniProt
- Q9Y5U5
Target
-